Shom Goel

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).

Reem Alomran, Michelle White, Melissa Bruce, Mathias Bressel, Susan Roache, Lama Karroum, Gerard G Hanna, Shankar Siva, Shom Goel, Steven David

Journal article  |  2021  |  BMC Cancer

BACKGROUND: The enhanced knowledge of cancer biology has led to considerable advancement in systemic therapy for advanced breast c..

CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity

April C Watt, Paloma Cejas, Molly J DeCristo, Otto Metzger-Filho, Enid YN Lam, Xintao Qiu, Haley BrinJones, Nikolas Kesten, Rhiannon Coulson, Alba Font-Tello, Klothilda Lim, Raga Vadhi, Veerle W Daniels, Joan Montero, Len Taing, Clifford A Meyer, Omer Gilan, Charles C Bell, Keegan D Korthauer, Claudia Giambartolomei, et al.

Journal article  |  2021  |  Nature Cancer

Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature.

Steven David, Gwo Ho, Daphne Day, Marion Harris, Jennifer Tan, Shom Goel, Gerard G Hanna, Ranjana Srivastava, Gill Kruss, Lachlan McDowell, Michelle White

Journal article  |  2021  |  Translational Oncology

Current first-line systemic treatment in most patients with metastatic hormone receptor-positive, HER-2 negative breast cancer is ..

Transforming growth factor beta in breast cancer: another new trick for the old dog

Kun-Hui Lu, Shom Goel

Journal article  |  2020  |  Immunology and Cell Biology

Trastuzumab-related cardiotoxicity: what do we know in 2020?

Jia Liu, Shom Goel, Jane McNeil Beith

Journal article  |  2020  |  Translational Cancer Research

Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial

Sara M Tolaney, Andrew M Wardley, Stefania Zambelli, John F Hilton, Tiffany A Troso-Sandoval, Francesco Ricci, Seock-Ah Im, Sung-Bae Kim, Stephen RD Johnston, Arlene Chan, Shom Goel, Kristen Catron, Sonya C Chapman, Gregory L Price, Zhengyu Yang, M Corona Gainford, Fabrice Andre

Journal article  |  2020  |  The Lancet Oncology

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Zuzana Kos, Elvire Roblin, Rim S Kim, Stefan Michiels, Brandon D Gallas, Weijie Chen, Koen K van de Vijver, Shom Goel, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O Nielsen, Sunil S Badve, W Fraser Symmans, Christos Sotiriou, David L Rimm, Stephen Hewitt, Carsten Denkert, Sibylle Loibl, Stephen J Luen, et al.

Journal article  |  2020  |  npj Breast Cancer

Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and HE..

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

Jan Hudecek, Leonie Voorwerk, Maartje van Seijen, Iris Nederlof, Michiel de Maaker, Jose van den Berg, Koen K van de Vijver, Karolina Sikorska, Sylvia Adams, Sandra Demaria, Giuseppe Viale, Torsten O Nielsen, Sunil S Badve, Stefan Michiels, William Fraser Symmans, Christos Sotiriou, David L Rimm, Stephen M Hewitt, Carsten Denkert, Sibylle Loibl, et al.

Journal article  |  2020  |  npj Breast Cancer

Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic tripl..

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Mohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, Jeppe Thagaard, Weijie Chen, Sarah Dudgeon, Ashish Sharma, Jennifer K Kerner, Carsten Denkert, Yinyin Yuan, Khalid AbdulJabbar, Stephan Wienert, Peter Savas, Leonie Voorwerk, Andrew H Beck, Anant Madabhushi, Johan Hartman, Manu M Sebastian, Hugo M Horlings, Jan Hudecek, et al.

Journal article  |  2020  |  npj Breast Cancer

Assessment of tumor-infiltrating lymphocytes (TILs) is increasingly recognized as an integral part of the prognostic workflow in t..

Monarcher: A Randomized Phase 2 Study of Abemaciclib Plus Trastuzumab with or without Fulvestrant Versus Trastuzumab Plus Standard-of-Care Chemotherapy in Women with HR , HER2 Advanced Breast Cancer

Johannes Ettl, Sara Tolaney, Andrew Wardley, Stefania Zambelli, John F Hilton, Francesco Ricci, Seock-Ah Im, Sung-Bae Kim, Stephen Johnston, Arlene Chan, Shom Goel, Kristen Catron, Zhengyu Yang, Corona Gainford, Fabrice Andre

Conference Proceedings  |  2020  |  ONCOLOGY RESEARCH AND TREATMENT